Quick Answer
AbCellera Biologics Inc. reported Total Revenue of $75.13 million for fiscal year 2025.
AbCellera Biologics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $75.13M +160.6% |
$28.83M -24.2% |
$38.02M -92.2% |
$485.42M +29.4% |
$375.20M +60.9% |
$233.16M +1907.9% |
| Revenue (ASC 606) | $75.13M +160.6% |
$28.83M -24.2% |
$38.02M -92.2% |
$485.42M +29.4% |
$375.20M +60.9% |
$233.16M +1907.9% |
| Net Income | -$146.41M +10.1% |
-$162.86M -11.2% |
-$146.40M -192.4% |
$158.52M +3.3% |
$153.46M +29.1% |
$118.92M +5478.5% |
| Diluted EPS | -$0.49 +10.9% |
-$0.55 -7.8% |
-$0.51 -202.0% |
$0.50 +4.2% |
$0.48 +6.7% |
$0.45 +4600.0% |
| Total Assets | $1.36B -0.3% |
$1.36B -8.6% |
$1.49B -3.4% |
$1.54B +16.9% |
$1.32B +31.1% |
$1.01B |
| Cash and Equivalents | $61.80M +11.2% |
$55.60M -58.3% |
$133.32M +196.9% |
$44.90M +447.6% |
$8.20M -98.6% |
$594.12M |
| Stockholders Equity | $966.90M -8.4% |
$1.06B -8.4% |
$1.15B -6.6% |
$1.23B +20.2% |
$1.03B +23.5% |
$830.51M +8000.9% |
| R&D Expense | $186.83M +11.7% |
$167.26M -4.8% |
$175.66M +62.8% |
$107.88M +73.8% |
$62.06M +111.1% |
$29.39M +190.6% |
| Operating Income | -$217.10M +31.0% |
-$314.77M -32.7% |
-$237.21M -209.6% |
$216.51M +5.9% |
$204.41M +31.0% |
$156.03M +3889.9% |
| Shares Outstanding | 300.60M +1.6% |
295.76M +1.7% |
290.82M +1.4% |
286.85M +1.3% |
283.26M +5.1% |
269.50M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $8.96M | +37.6% | -47.6% |
| Revenue (ASC 606) | September 30, 2025 | $8.96M | +37.6% | -47.6% |
| Net Income | September 30, 2025 | -$57.12M | -11.8% | -64.5% |
| Diluted EPS | September 30, 2025 | -$0.19 | -11.8% | -58.3% |
| Total Assets | September 30, 2025 | $1.36B | -2.6% | -3.3% |
| Cash and Equivalents | September 30, 2025 | $83.16M | -34.3% | -10.0% |
| Stockholders Equity | September 30, 2025 | $964.04M | -10.6% | -4.3% |
| R&D Expense | September 30, 2025 | $55.03M | +34.3% | +40.3% |
| Operating Income | September 30, 2025 | -$76.28M | +18.6% | -53.8% |
| Shares Outstanding | September 30, 2025 | 299.01M | +2.8% | +1.1% |
- AbCellera Biologics Inc. reported Total Revenue of $75.13 million for fiscal year 2025.
- AbCellera Biologics Inc. showed an increase of +160.6% in Total Revenue compared to the prior fiscal year.
- AbCellera Biologics Inc. reported Revenue (ASC 606) of $75.13 million for fiscal year 2025.
- AbCellera Biologics Inc. showed an increase of +160.6% in Revenue (ASC 606) compared to the prior fiscal year.
- AbCellera Biologics Inc. reported Net Income of -$146.41 million for fiscal year 2025.
- AbCellera Biologics Inc. showed an increase of +10.1% in Net Income compared to the prior fiscal year.
- AbCellera Biologics Inc. reported Diluted EPS of $0.49 per share (loss) for fiscal year 2025.
- AbCellera Biologics Inc. showed an increase of +10.9% in Diluted EPS compared to the prior fiscal year.
- AbCellera Biologics Inc. reported Total Assets of $1.36 billion for fiscal year 2025.
- AbCellera Biologics Inc. showed a decrease of -0.3% in Total Assets compared to the prior fiscal year.
- AbCellera Biologics Inc. reported Cash and Equivalents of $61.80 million for fiscal year 2025.
- AbCellera Biologics Inc. showed an increase of +11.2% in Cash and Equivalents compared to the prior fiscal year.
- AbCellera Biologics Inc. reported Stockholders Equity of $966.90 million for fiscal year 2025.
- AbCellera Biologics Inc. showed a decrease of -8.4% in Stockholders Equity compared to the prior fiscal year.
- AbCellera Biologics Inc. reported R&D Expense of $186.83 million for fiscal year 2025.
- AbCellera Biologics Inc. showed an increase of +11.7% in R&D Expense compared to the prior fiscal year.
- AbCellera Biologics Inc. reported Operating Income of -$217.10 million for fiscal year 2025.
- AbCellera Biologics Inc. showed an increase of +31.0% in Operating Income compared to the prior fiscal year.
- AbCellera Biologics Inc. reported Shares Outstanding of 300.60 million shares for fiscal year 2025.
- AbCellera Biologics Inc. showed an increase of +1.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: